Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma.

Dickinson, Michael; Briones, Javier; Herrera, Alex F; González-Barca, Eva; Ghosh, Nilanjan; Cordoba, Raul; Rutherford, Sarah C; Bournazou, Eirini; Labriola-Tompkins, Emily; Franjkovic, Izolda; Chesne, Evelyne; Brouwer-Visser, Jurriaan; Lechner, Katharina; Brennan, Barbara; Nüesch, Eveline; DeMario, Mark; Rüttinger, Dominik; Kornacker, Martin; Hutchings, Martin

Dickinson, Michael; Briones, Javier; Herrera, Alex F; González-Barca, Eva; Ghosh, Nilanjan; Cordoba, Raul; Rutherford, Sarah C; Bournazou, Eirini; Labriola-Tompkins, Emily; Franjkovic, Izolda; Chesne, Evelyne; Brouwer-Visser, Jurriaan; Lechner, Katharina; Brennan, Barbara; Nüesch, Eveline; DeMario, Mark; Rüttinger, Dominik; Kornacker, Martin; Hutchings, Martin.

Affiliation

Dickinson M; Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia.
Briones J; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
Herrera AF; Hematology Department, Hospital de la Santa Creu i Sant Pau, Sant Pau, Spain.
González-Barca E; Jose Carreras Leukemia Research Institutes, Autonomous University of Barcelona, Barcelona, Spain.
Ghosh N; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.
Cordoba R; Department of Hematology, Institut Català d'Oncologia, Hospital duran i Reynals, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, L'Hospitalet de LLobregat, Barcelona, Spain.
Rutherford SC; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC.
Bournazou E; Department of Hematology, Fundacion Jimenez Diaz University Hospital, Madrid, Spain.
Labriola-Tompkins E; Meyer Cancer Center, Division of Hematology and Medical Oncology, Weill Department of Medicine, NewYork-Presbyterian Hospital, Weill Cornell Medicine, New York, NY.
Franjkovic I; Roche Innovation Center New York, Roche Pharma Research and Early Development, New York, NY.
Chesne E; Roche Innovation Center New York, Roche Pharma Research and Early Development, New York, NY.
Brouwer-Visser J; Roche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany.
Lechner K; Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland.
Brennan B; Roche Innovation Center New York, Roche Pharma Research and Early Development, New York, NY.
Nüesch E; Roche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany.
DeMario M; Roche Innovation Center New York, Roche Pharma Research and Early Development, New York, NY.
Rüttinger D; Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland.
Kornacker M; Roche Innovation Center New York, Roche Pharma Research and Early Development, New York, NY.
Hutchings M; Roche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany.

Blood Adv ; 5(22): 4762-4770, 2021 11 23.

Article de En | MEDLINE | ID: mdl-34581757

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Protocoles de polychimiothérapie antinéoplasique / Lymphome B diffus à grandes cellules Type d'étude: Prognostic_studies Limites: Humans Langue: En Journal: Blood Adv Année: 2021 Type de document: Article Pays d'affiliation: Australie Pays de publication: États-Unis d'Amérique

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google